{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-016698","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2021-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.315717+00:00","generated_at":"2026-06-28T01:37:15.443073+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CFO Richard Eisenstadt resigns effective Dec 30, 2021; successor search underway","bullets":["Richard I. Eisenstadt resigns as CFO effective Dec 30, 2021 to pursue opportunity at another development-stage pharma.","Resignation not due to any disagreements with Company's operations, policies, practices, or auditors.","Company has initiated a search to identify and recruit a new CFO; CEO Josh Disbrow signing the filing.","No interim CFO named; current CFO to depart at month-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-016698","json":"https://secwatch.observer/filing/0001558370-21-016698.json","markdown":"https://secwatch.observer/filing/0001558370-21-016698.md","text":"https://secwatch.observer/filing/0001558370-21-016698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000155837021016698/0001558370-21-016698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000155837021016698/aytu-20211208x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T01:37:15.443073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1564fcd4e9","claim":"Richard I. Eisenstadt resigned as Chief Financial Officer at AYTU BIOPHARMA, INC.","evidence_excerpt":"On December 8, 2021, Richard I. Eisenstadt resigned as Chief Financial Officer of Aytu BioPharma, Inc. (the “Company”), effective December 30, 2021, to pursue another opportunity at a development-stage pharmaceutical company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000155837021016698/0001558370-21-016698-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}